62 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
25 Oct 23
Akebia Receives FDA Acceptance of Resubmission to NDA of
4:06pm
on dialysis, was complete. The FDA has classified this as a class 2 response, which results in a six-month review period from the date of resubmission
424B5
vff9viwo2dspy4x 2pz8
7 Apr 22
Prospectus supplement for primary offering
4:36pm
POS AM
b06qi5gdkroliu
1 Mar 22
Prospectus update (post-effective amendment)
5:09pm
POSASR
oomrvj oc
1 Mar 22
Automatic shelf registration (post-effective amendment)
4:12pm
S-3ASR
393e9axc8ce7tkf08mw
25 Feb 21
Automatic shelf registration
5:21pm